Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Stabilization and exclusions
Airway compromise
If stridor or inability to handle secretions, airway escalation
Stroke exclusion
If acute focal deficits beyond facial nerve, stroke pathway
CNS infection exclusion
If fever and meningismus, CNS infection pathway
Temporal bone trauma exclusion
If head trauma and ear bleeding, temporal bone fracture pathway
Eye protection urgency
If incomplete eyelid closure, immediate corneal protection
Time critical decision points
High risk features requiring alternate diagnosis
Gradual progressive weakness beyond 72 hours
MRI brain and internal auditory canal consideration
Recurrent ipsilateral facial palsy
Tumor or structural lesion evaluation
Bilateral facial palsy
Lyme disease and Guillain Barre syndrome evaluation
Vesicular rash or severe otalgia
Ramsay Hunt syndrome consideration
Facial palsy with parotid mass
Neoplasm evaluation
Facial palsy with hyperacusis and taste change
Peripheral facial nerve localization support
History
Key history elements
Symptom characterization
Onset timing
Hours to 1 to 2 days typical
Progression pattern
Maximal weakness within 72 hours typical
Laterality
Unilateral typical
Prior episodes
Recurrence risk factor for alternate etiology
Pain
Retroauricular pain common early
Eye symptoms
Dryness
Foreign body sensation
ENT symptoms
Hyperacusis
Taste disturbance anterior tongue
Reduced lacrimation
Recent viral syndrome
Upper respiratory infection prodrome
Rash history
Ear or oral vesicles
Tick exposure
Travel or outdoor exposure in endemic region
Systemic symptoms
Fever
Arthralgias
Weight loss
Immunocompromise
HIV risk factors
Transplant or steroids
Pregnancy status
Third trimester and postpartum risk
Pitfalls
Historical red flags
Limb weakness or numbness
Central cause consideration
Dysarthria or dysphagia
Brainstem process consideration
Diplopia or vertigo
Posterior circulation process consideration
Hearing loss or severe vertigo
Ramsay Hunt or other otologic pathology consideration
Physical Exam
Focused neuro and head and neck
Facial nerve distribution
Forehead involvement
Inability to raise eyebrow supports peripheral palsy
Eye closure strength
Lagophthalmos severity grading
Smile and nasolabial fold
Asymmetry and droop severity grading
Synkinesis baseline
Involuntary co contraction if chronic or prior episodes
Taste and lacrimation adjuncts
Anterior tongue taste change support
Dry eye risk assessment
Cranial nerve screen
Pupils and extraocular movements
Abnormalities support central process
Hearing gross assessment
Asymmetry supports Ramsay Hunt or other lesion
Palate elevation and tongue deviation
Abnormalities support brainstem lesion
Skin and ear exam
External ear canal and pinna
Vesicles support Ramsay Hunt syndrome
Oral mucosa
Vesicles or ulcers support herpes zoster
Parotid gland exam
Mass supports neoplasm
Eye exam
Corneal integrity
Fluorescein staining if exposure symptoms
Conjunctival injection
Exposure keratopathy indicator
Severity grading
Facial palsy grading tools
House Brackmann grade
Grade I normal
Grade VI total paralysis
Sunnybrook score
Resting symmetry
Voluntary movement
Synkinesis
Differential Diagnosis
Life threatening and must not miss
Central causes
Ischemic stroke involving corticobulbar pathways
ICD-10 I63
Intracranial hemorrhage
ICD-10 I61
Brainstem tumor or mass
ICD-10 D49.6
Neuromuscular causes
Guillain Barre syndrome
ICD-10 G61.0
Myasthenia gravis
ICD-10 G70.00
Peripheral facial palsy causes
Idiopathic facial nerve palsy
Bell palsy
ICD-10 G51.0
SNOMED CT concept facial nerve palsy idiopathic
Infectious
Herpes zoster oticus
Ramsay Hunt syndrome
ICD-10 B02.21
Lyme disease
Neuroborreliosis facial palsy
ICD-10 A69.2
Otitis media or mastoiditis associated palsy
ICD-10 H66 and H70
HIV associated facial palsy
ICD-10 B20
Structural
Parotid malignancy or benign tumor
ICD-10 C07 and D11
Temporal bone fracture
ICD-10 S02.19
Inflammatory and systemic
Sarcoidosis
ICD-10 D86
Multiple sclerosis
ICD-10 G35
Laboratory Tests
When labs are indicated
Targeted testing strategy
Typical isolated Bell palsy
No routine labs needed
Clinical diagnosis supported by peripheral pattern
Lyme risk or endemic exposure
Two tier serology
EIA or ELISA screening
Immunoblot confirmation per local protocol
Vesicular rash or immunocompromise
Varicella zoster virus testing if diagnosis unclear
PCR from lesion if present
Systemic features or bilateral palsy
Basic labs for alternative etiologies
Complete blood count for infection or hematologic concern
Electrolytes for systemic illness context
Diabetes risk or severe palsy
HbA1c consideration
Prognosis association with diabetes
Diagnostic Tests
Scoring Systems
Severity and prognosis tools
House Brackmann grading
Higher grade at presentation predicts slower recovery
Grade V to VI supports consideration of adjunct antiviral therapy
Sunnybrook facial grading system
Baseline documentation for follow up comparison
Synkinesis tracking during recovery
MRI
Indications for MRI brain and internal auditory canal
Atypical features
Gradual progression beyond 72 hours
No improvement by 3 months
Recurrent facial palsy
Tumor or structural lesion evaluation
Multiple cranial neuropathies
Inflammatory or infiltrative process evaluation
Findings compatible with Bell palsy
Facial nerve enhancement possible but nonspecific
CT
Indications for CT head or temporal bone
Trauma history
Temporal bone CT for suspected fracture
Otitis media complications
Mastoiditis evaluation if severe otalgia and fever
Concern for stroke or hemorrhage
Noncontrast CT head if central features
Ultrasound
Point of care applications
Parotid and neck ultrasound
Palpable mass evaluation support
No routine role for Bell palsy diagnosis
Use limited to alternate diagnoses
Disposition
Site of care decisions
Disposition criteria
Outpatient management typical
Stable vitals
Isolated peripheral facial palsy pattern
Eye protection plan established
Admission or observation indications
Inability to protect cornea
Severe lagophthalmos with corneal injury
Suspected stroke or CNS infection
Neuroimaging and specialist evaluation needs
Severe pain with Ramsay Hunt syndrome
Hydration and analgesia needs
Immunocompromised with suspected disseminated infection
IV therapy consideration
Follow up timing
Primary care or ENT within 1 week
Ophthalmology within 24 to 72 hours if incomplete eye closure
Treatment
First line therapy
Corticosteroids
Prednisone or prednisolone initiation within 72 hours
Prednisone 60 mg PO daily for 5 days
Then 40 mg PO daily for 5 days
Total 10 day course
Prednisone 50 mg PO daily for 10 days alternative
No taper option per local practice
Key counseling
Greatest benefit when started early
Avoid delay for imaging in typical cases
Eye protection
Artificial tears
Preservative free drops every 1 to 2 hours while awake
Increase frequency with dryness
Lubricating ointment
At bedtime
Use with taping or moisture chamber
Eyelid taping
Nightly if incomplete closure
Ensure lashes not abrading cornea
Ophthalmology referral triggers
Corneal pain
Same day evaluation
Decreased vision
Same day evaluation
Corneal staining
Prompt evaluation
Adjunctive antiviral therapy
Antivirals with steroids
Consider for severe palsy
House Brackmann V to VI
Shared decision making
Valacyclovir
1000 mg PO three times daily for 7 days
Renal dose adjustment required
Acyclovir alternative
400 mg PO five times daily for 10 days
Adherence limitations
Evidence framing
Steroids high benefit for complete recovery
Class I recommendation common in neurology guidelines
Antiviral incremental benefit small and greatest in severe cases
Class IIb recommendation reasonable
Ramsay Hunt syndrome pathway
Herpes zoster oticus management
Antiviral plus corticosteroid recommended
Valacyclovir 1000 mg PO three times daily for 7 to 10 days
Start as early as possible
Prednisone regimen as above
Use with antiviral
Analgesia
Acetaminophen weight based or standard dosing
Avoid exceeding daily maximum
NSAID if no contraindication
GI and renal risk review
ENT follow up
Hearing symptoms or vertigo
Urgent referral
Symptom control and rehab
Pain control
Acetaminophen
650 to 1000 mg PO every 6 to 8 hours as needed
Max 4000 mg per 24 hours
Ibuprofen
400 mg PO every 6 to 8 hours as needed
Max 2400 mg per 24 hours typical
Facial physical therapy
Consider for severe palsy or prolonged recovery
Guidance to avoid excessive forced exercises early
Synkinesis management in chronic phase
Specialist referral consideration
Antibiotics
Not indicated for idiopathic Bell palsy
Use only if otitis media or other bacterial diagnosis present
Special Populations
Pregnancy
Pregnancy considerations
Higher incidence in third trimester and early postpartum
Preeclampsia association consideration
Steroid use
Prednisone and prednisolone generally compatible with pregnancy
Lowest effective duration
Antiviral use
Valacyclovir generally considered acceptable when indicated
Obstetric input for individualized risk
Alternative diagnosis vigilance
Headache or hypertension
Preeclampsia evaluation
Geriatric
Older adult considerations
Higher baseline stroke risk
Lower threshold for neuroimaging if atypical features
Steroid adverse effects
Hyperglycemia monitoring plan
Delirium risk counseling
Eye complication risk
Early ophthalmology if severe lagophthalmos
Pediatrics
Pediatric considerations
Common infectious differentials
Lyme disease in endemic regions
Otitis media related palsy
Steroid dosing
Prednisone 1 mg per kg per day
Max 60 mg per day
5 days then taper 5 days common regimen
Antiviral use
Consider in severe palsy or zoster suspicion
Weight based dosing per local pediatric formulary
Safeguarding eye care
Caregiver instruction for drops and taping
Background
Epidemiology
Population features
Most common cause of acute unilateral peripheral facial paralysis
Incidence commonly cited around 15 to 30 per 100000 per year
Age distribution
Broad distribution with peak in adults
Risk factors
Pregnancy
Diabetes mellitus
Recent viral illness
Pathophysiology
Mechanism
Acute inflammation and edema of facial nerve
Compression within facial canal
Ischemia and conduction block
Viral reactivation hypothesis
Herpes simplex virus type 1 association proposed
Clinical localization
Lower motor neuron pattern
Forehead involvement due to peripheral lesion
Therapeutic Considerations
Rationale for steroids
Reduction of nerve edema and inflammation
Improved odds of complete recovery when early
Rationale for antivirals
Possible viral contribution
Greatest theoretical benefit in severe palsy
Prognosis counseling
Majority achieve substantial recovery
Early improvement predicts better outcome
Poor prognostic factors
Complete paralysis at onset
Older age
Diabetes mellitus
Delayed steroid initiation
Patient Discharge Instructions
copy discharge instructions
Discharge instructions
Diagnosis explanation
Bell palsy is a weakness of the facial nerve causing one sided facial droop
Medications
Take steroid exactly as prescribed
Take antiviral if prescribed
Eye care
Artificial tears often during the day
Ointment at night
Tape eyelid closed during sleep if it does not fully close
Expected course
Symptoms often worsen for up to 2 to 3 days then stabilize
Improvement often begins within weeks
Follow up
Primary care or ENT within 1 week
Eye doctor urgently if eye pain or vision changes
Return to emergency care now for
New arm or leg weakness or numbness
Trouble speaking or trouble walking
Severe headache
Fever or stiff neck
New double vision
Worsening vision
Eye pain or inability to keep eye moist
Spreading rash or ear vesicles with severe dizziness
References
Guidelines and key sources
Evidence base
American Academy of Neurology guideline on steroids and antivirals for Bell palsy
Steroids early for improved complete recovery
Otolaryngology guidance on eye protection in facial nerve palsy
Corneal protection as highest priority
Infectious disease guidance for Lyme associated facial palsy testing and treatment
Two tier serology and region specific epidemiology
Source specification
Clinical management system formatting and nesting requirements
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.